The FDA has cleared HuidaGene Therapeutics' investigational new drug application for HG202, the first CRISPR-Cas13 RNA-editing therapy to enter...
In this clinical update, we bring you the latest news from four gene-editing trials sponsored by RenJi Hospital (Shanghai), The University of Texas MD...
Last week, Vor Bio announced new, encouraging clinical data from the ongoing Phase 1/2 VBP101 trial of trem-cel followed by the anti-CD33...
YolTech Therapeutics announced last week that the first two patients have been dosed in a Phase 1 trial of YOLT-203, an in vivo CRISPR-based...
US-based Locus Biosciences recently reported positive pharmacokinetic and safety data from the first part of the ongoing Phase 2 trial of...
Intellia Therapeutics announced yesterday that the UK’s Medicine and Healthcare products Regulatory Agency has cleared its clinical trial application...
In this clinical update, we bring you the latest news from four gene-editing trials sponsored by Beam Therapeutics, Intellia Therapeutics, Editas...
In this brief update, we bring you the latest news from three gene-editing clinical trials sponsored by Cellectis, Intellia Therapeutics and Caribou...
